GlassScriptPhysician profile
Rajat Sood
NPI 1962504126
$257,597.61
in general payments reported to CMS, 2019-2025
43 companies · $88K in 2025
The $88K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $8,877 · 2021: $14K · 2022: $22K · 2023: $12K · 2024: $87K · 2025: $88K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $147K · Travel and Lodging: $28K · Food and Beverage: $9,854 · Honoraria: $3,000 · Education: $180 · Gift: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $147,157.00 |
| Travel and Lodging | $28,012.10 |
| Food and Beverage | $9,854.17 |
| Honoraria | $3,000.00 |
| Education | $179.95 |
| Gift | $122.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $137,970.97 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $106,032.04 | 2019-2025 | Epclusa |
| Intra-Sana Laboratories | $3,856.62 | 2021-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Abbvie INC. | $2,660.18 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Pfizer INC. | $896.03 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $834.49 | 2019-2025 | Xifaxan, Plenvu |
| Braintree Laboratories, INC. | $681.65 | 2019-2024 | Sutab, Suflave |
| Qol Medical, LLC | $609.12 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $569.63 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $553.43 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $378.51 | 2024-2025 | Vowst |
| Ferring Pharmaceuticals INC. | $363.87 | 2019-2025 | Rebyota |
| Phathom Pharmaceuticals, INC. | $277.70 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $194.21 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $186.10 | 2019-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajat Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.